Eli Lilly launches Mounjaro® KwikPen® to advance care for adults with Type 2 Diabetes and obesity in India

Eli Lilly and Company (India) has announced that Mounjaro^® KwikPen^® (tirzepatide) is now available across India in all doses.

Approved by the Central Drugs Standard Control Organisation (CDSCO), Mounjaro^® KwikPen^®, a prescription-based, once-weekly treatment, offers a convenient way for patients to administer their medication.

Mounjaro^® is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of:

• Type 2 diabetes
• Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.

Mounjaro^® KwikPen^® is a multi-dose, single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly.  The pen will be available in six dose strengths: 2.5 mg (Rs 14000), 5 mg (Rs 17500), 7.5 mg (Rs 22000), 10 mg (Rs 22000), 12.5 mg (Rs 27500), and 15 mg (Rs 27500), allowing healthcare professionals to personalise treatment plans to better suit individual patient needs.

Mounjaro^® is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. It is not approved for—and must not be used for—cosmetic weight loss.